Brasília – Brazil’s National Health Surveillance Agency (Anvisa) has approved the registration of Qfitlia (fitusiran sodium), a new therapy indicated for patients with hemophilia A or B, with or without inhibitors to clotting factors VIII or IX. The drug can be used both for prophylaxis and for reducing the frequency of bleeding episodes, one of the main complications associated with the rare genetic disorder.

Developed by Sanofi, the treatment is indicated for adults and adolescents aged 12 and older and works by lowering levels of antithrombin, a protein that slows blood clotting, thereby helping restore the balance of the coagulation system. Brazil has more than 14,000 diagnosed hemophilia patients, and the approval adds a new therapeutic option to the country’s treatment landscape.

Source: G1